Abstracts Archive - Page 967 of 2425 - ACR Meeting Abstracts

Abstract Number: 190 • 2019 ACR/ARP Annual Meeting
Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis
Bryant England¹, Punyasha Roul ², Tina Mahajan ³, Namrata Singh ⁴, Fang Yu ², Harlan Sayles ², Grant Cannon ⁵, Brian Sauer ⁵, Joshua Baker ⁶, Jeffrey Curtis ⁷ and Ted Mikuls ⁸, ¹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ⁴University of Iowa, Iowa City, ⁵Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of RA patients leading to significant disability and premature mortality. While large administrative datasets have been widely leveraged…
Abstract Number: 191 • 2019 ACR/ARP Annual Meeting
Associations of Self-Reported Inhalant Exposures with Autoantibodies and Disease Severity in U.S. Veterans with Rheumatoid Arthritis
Ariadne Ebel¹, Jill Poole ², Geoffrey Thiele ³, Joshua Baker ⁴, Grant Cannon ⁵, Angelo Gaffo ⁶, Gail Kerr ⁷, Andreas Reimold ⁸, John S. Richards ⁹, Pescale Schwab ¹⁰, Namrata Singh ¹¹, Dana Ascherman ¹², Ted Mikuls ³ and Bryant England ¹³, ¹University of Nebraska, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, ⁸UT Southwestern Medical Center, Dallas, ⁹VA Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁰VA Portland Healthcare System, Porland, ¹¹University of Iowa, Iowa City, ¹²University of Pittsburgh, Pittsburgh, ¹³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Cigarette smoke is a known inhalant exposure that contributes substantially to the risk and severity of rheumatoid arthritis (RA). Less is known about the…
Abstract Number: 192 • 2019 ACR/ARP Annual Meeting
A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women
Nathalie Marchand¹, Shilpa Bhupathiraju ², Megu Baden ², Jeffrey Sparks ³, Susan Malspeis ³, Karen Costenbader ³, Elizabeth Karlson ³ and Bing Lu ³, ¹Brigham and Women's Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Consuming an overall healthy diet has been associated with a reduced risk of developing rheumatoid arthritis (RA), but the impact of consuming a diet…
Abstract Number: 193 • 2019 ACR/ARP Annual Meeting
Diet as a Risk Factor for Rheumatoid Arthritis
Chelsea Guan ¹ and Shazia Beg², ¹University of Central Florida, Orlando, ²University of Central Florida College of Medicine, Orlando
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease affecting the joints that typically affects women more than men. An exact cause has yet…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 195 • 2019 ACR/ARP Annual Meeting
The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Luke Monteagudo¹, Amy Gravely ², Peter Valen ³ and David Ewart ³, ¹The University of Minnesota, Minneapolis, ²Minneapolis Veteran Affairs Medical Center, Minneapolis, ³University of Minnesota School of Medicine/ Minneapolis Veteran Affairs Medical Center, Minneapolis
Background/Purpose: Background: The biochemical hallmark of hypophosphatasia (HPP) is a low alkaline phosphatase (ALP) level. It is recognized that some forms of HPP present in adulthood…
Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…
Abstract Number: 197 • 2019 ACR/ARP Annual Meeting
The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Harriet Dickinson ¹, Yunhao Liu ² and Rachel Williams³, ¹GSK, Stevenage, United Kingdom, ²GSK, Upper providence, ³GSK, Upper Providence, PA
Background/Purpose: Pain is one of the most pressing problems for Rheumatoid Arthritis (RA) patients and contributes substantially towards fatigue and disability. Experiences of pain in…
Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Mark Yates¹, Sam Norton ¹, Alexander MacGregor ², Katie Bechman ³, Sanketh Rampes ³ and James Galloway ⁴, ¹Kings College London, London, ²University of East Anglia, Norwich, United Kingdom, ³King's College London, London, United Kingdom, ⁴Kings College London, London, United Kingdom
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
Abstract Number: 199 • 2019 ACR/ARP Annual Meeting
Obesity and Incident Opioid Use in Rheumatoid Arthritis
Joshua Baker¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prevalent chronic use of opioids approximately 17% among patients with rheumatoid arthritis (RA) and has increased over the last decade.(1) Obesity may be a…
Abstract Number: 200 • 2019 ACR/ARP Annual Meeting
A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records
Tjardo Maarseveen¹, Thomas Huizinga ¹, Marcel J.T. Reinders ¹, Erik van den Akker ¹ and Rachel Knevel ¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rapidly expanding collections of Electronic Medical Records (EMR) form a valuable resource for clinical research. Besides entries with a standardized format, EMRs often also…
Abstract Number: 201 • 2019 ACR/ARP Annual Meeting
Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies
Runsheng Wang¹, Thomas Falconer ² and George Hripcsak ², ¹Columbia University Medical Center, Division of Rheumatology, New York City, ²Columbia University Medical Center, Department of Biomedical Informatics, New York City
Background/Purpose: To improve efficiency and transportability of observational research, common data models have been developed and maintained to translate data from source vocabularies into standardized…
Abstract Number: 202 • 2019 ACR/ARP Annual Meeting
Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian P. Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Biosimilar use in North America is relatively low, and real-world comparisons of biosimilars and their originator biologics are lacking. We assessed risk factors associated…
Abstract Number: 203 • 2019 ACR/ARP Annual Meeting
Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York City, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In North America, biosimilars were approved only relatively recently, and real-world data are few. We described users of infliximab in the US, comparing patient…
Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Magdaliz Gorritz ³, Lawrence Chang ², Jing He ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].